Results 161 to 170 of about 14,007,730 (234)

Seeking new or outside employment

open access: yes, 2010
Title from PDF caption (viewed on Feb. 10, 2010).; "Rev'd March 2005"--P. 3.; "Created: 1/12/2010 ..."--Document properties screen.; Includes bibliographical references.; Harvested from the web on 2/10/10The Ethics Commission prepared this information ...

core  

Research ethics review during the COVID-19 pandemic: An international study

open access: yes, 2023
Salamanca-Buentello F   +4 more
europepmc   +1 more source

Understanding Further the Phenotypic Spectrum of Central Nervous System Inflammatory Demyelinating Disorders Using Unsupervised Clustering

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Central nervous system (CNS) inflammatory demyelinating syndromes, including multiple sclerosis (MS), aquaporin‐4 antibody–positive neuromyelitis optica spectrum disorder (AQP4 + NMOSD), and myelin oligodendrocyte glycoprotein (MOG) antibody–associated disease (MOGAD), occasionally overlap.
Bade Gulec   +6 more
wiley   +1 more source

Confidentiality & the ethics law

open access: yes, 2013
Bimonthly, Aug. 2013-; Monthly, Feb. 2013-June 2013; Feb. 2013-; Newsletter.; "A publication of the Ohio Ethics Commission"--Aug.
Ohio Ethics Commission.
core  

Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: A Comparison With Rituximab

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy